The impact of mycobacterium avium complex bacteremia and its treatment on survival of aids patients-a prospective study

Journal of Infectious Diseases

Volumn 170, Issue 3, 1994, Pages 578-584

  Chin, Daniel P ^a,b,c   Reingold, Arthur L ^a,b,c   Stone, Elizabeth N ^a,b,c   Vittinghoff, Eric ^a,b,c   Horsburgh, C Robert ^a,b,c   Simon, Ellen M ^a,b,c   Yajko, David M ^a,b,c   Keith Hadley, W ^a,b,c   Ostroff, Stephen M ^a,b,c   Hopewell, Philip C ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCOBACTERIAL AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BACTEREMIA; CHEMOPROPHYLAXIS; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MYCOBACTERIUM INTRACELLULARE AVIUM; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBIOTICS; ANTIBIOTICS, COMBINED; ANTIBIOTICS, MACROLIDE; BACTEREMIA; CD4-POSITIVE T-LYMPHOCYTES; COMPARATIVE STUDY; DEMOGRAPHY; HUMAN; MULTIVARIATE ANALYSIS; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0028132862     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/170.3.578     Document Type: Article

References (20)

1. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med 1993; 329:1922-6.
2. Chiu J, Nussbaum J, Bozzette S, et al. Treatment ofdisseminated Mycobacterium avium complex infection in AIDS with amikacin, etham-butol, rifampin, and ciprofloxacin. Ann Intern Med 1990; 113:358-61.
3. Kemper CA, Meng TC, Nussbaum J, et al. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Ann Intern Med 1992; 116:466-72.
4. Young LS. Wiviott L, Wu M, Kolonoski P, Bolan R, Inderlied CB. Azithromycin for treatment of Mycobacterium avium-inlracellulare complex infection in patients with AIDS. Lancet 1991;338:1107-9.
5. Horsburgh CR Jr., Havlik JA, Ellis DA, et al.Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am Rev Respir Dis 1991;144:557-9.
6. Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T, Zidovudine Epidemiology Study Group. Incidence and natural history of Mycobacterium avium complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. Am Rev Respir Dis 1992;146:285-9.
7. Kerlikowske KM, Katz MH, Chan AK, Perez-Stable EJ. Antimycobacterial therapy for disseminated Mycobacterium avium complex infection in patients with acquired immunodeficiency syndrome. Arch Intern Med 1992;152:813-7.
8. Masur H, Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N Engl J Med 1993;329:898-904.
9. Roberts GD, Koneman EW, Kin YK. Mycobacterium. In: Balows A, Hausier WJ Jr, Herrmann KL, Isenberg HD, Shadomy HJ, eds. Manual of clinical microbiology. Washington, DC: American Society for Microbiology, 1991:304-39.
10. Cox DR, Oakes D. Cox proportional hazard model In: Analysis of survival data. New York: Chapman and Hall, 1984:48-53, 91-138.
11. SAS user’s guide: Statistics. Cary, NC: SAS Institute, 1991.
12. Dautzenberg B, Truflot C, Legris S, et al. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. Am Rev Respir Dis 1991;144:564-9.
13. Sathe SS, Gascone P, Lo W, Pinto R, Reichman LB. Severe anemia is an important negative predictor for survival with disseminated Mycobacterium avium-intraceliuiare in acquired immunodeficiency syndrome. Am Rev Respir Dis 1990;142:1306-12.
14. Phillips AN, Flford J, Sabin C, Bofill M, Janossy G, Lee CA. Immunodeficiency and the risk of death in HIV infection. JAMA 1992;268:2662-6.
15. Creagh-Kirk T, Doi P, Andrews E, et al. Survival experience among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea program. JAMA 1988;260:3009-15.
16. Lemp GF, Payne SF, Neal D, Temelso T, Rutherford GW. Survival trends for patients with AIDS. JAMA 1990;263:402-6.
17. Moore RD, Hidalgo J, Sugland BW, Chaisson RE. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med 1991;324:1412-6.
18. Lindan CP, Allen S, Serufilira A, et al. Predictors of mortality among HIV-infected women in Kigali, Rwanda. Ann Intern Med 1992;116:320-8.
19. Graham NMH, Zeger SL, Park LP, et al. The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med 1992;326:1037-42.
20. Chlebowski RT, Grosvenor MB, Bernhard NH, Morales LS, Bulcavage LM. Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. Am J Gastroenterol 1989;84:1288-93.